Characterization of a Tumor Necrosis Factor Alpha (TNF-alpha) Inhibitor: Evidence of Immunological Cross-reactivity with the TNF Receptor

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1990 Jul 1

PMID 2164226

Citations 34

Authors

P Seckinger

J H Zhang

B Hauptmann

J M Dayer

Affiliations

Soon will be listed here.

Abstract

Previous studies have shown that urine of febrile patients contains a tumor necrosis factor alpha inhibiting activity (TNF-alpha Inh) when tested in a cytotoxicity assay using the tumor necrosis factor alpha (TNF-alpha)-susceptible cell line L929. In the present study, we investigated the relationship between the TNF-alpha Inh and a potential soluble form of the receptor, as the former has been shown to block TNF-alpha activities by binding to the ligand. We demonstrate that human TNF-alpha is affected to a greater extent than is murine TNF-alpha. This species specificity of the inhibitor correlates with the binding studies of TNF receptor interactions already reported. We raised a polyclonal antibody to TNF-alpha Inh that neutralizes its activity and does not recognize TNF-alpha. Solubilized cross-linked 125I-labeled TNF-alpha receptor complex could be immunoprecipitated by using either anti-TNF-alpha or anti-TNF-alpha Inh antibody, suggesting immunological cross-reactivity between the receptor and the inhibitor. By using fluorescein isothiocyanate-coupled TNF-alpha, it was possible to visualize by fluorescence-activated cell sorter analysis the TNF-alpha receptor on phytohemagglutinin/interleukin 2-activated T cells. A similar increase of immunofluorescence intensity of the activated T cells was observed by using anti-TNF-alpha Inh antibody revealed with a fluorescein isothiocyanate-coupled goat anti-rabbit IgG1 conjugate, suggesting that the TNF-alpha Inh is also expressed as a membrane protein. Taken together, our results suggest that the TNF-alpha Inh originally described might be a soluble form of the TNF receptor itself.

Citing Articles

Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing.

Lee C, Kim T, Hong S, Chu J, Kang J, Park H Front Pharmacol. 2021; 11:608774.

PMID: 33505314 PMC: 7832035. DOI: 10.3389/fphar.2020.608774.

Serum cytokine profiles in healthy nonhuman primates are blunted by sedation and demonstrate sexual dimorphism as detected by a validated multiplex immunoassay.

Hocum Stone L, Oppler S, Nugent J, Gresch S, Hering B, Murtaugh M Sci Rep. 2021; 11(1):2340.

PMID: 33504894 PMC: 7840937. DOI: 10.1038/s41598-021-81953-7.

From supernatants to cytokines: a personal view on the early history of IL-1, IL-1Ra, TNF and its inhibitor in rheumatology.

Dayer J Arthritis Res Ther. 2018; 20(1):101.

PMID: 29848388 PMC: 5977557. DOI: 10.1186/s13075-018-1607-y.

Biologics for Targeting Inflammatory Cytokines, Clinical Uses, and Limitations.

Rider P, Carmi Y, Cohen I Int J Cell Biol. 2017; 2016:9259646.

PMID: 28083070 PMC: 5204077. DOI: 10.1155/2016/9259646.

Tumor necrosis factor-alpha and the roles it plays in homeostatic and degenerative processes within the central nervous system.

Montgomery S, Bowers W J Neuroimmune Pharmacol. 2011; 7(1):42-59.

PMID: 21728035 DOI: 10.1007/s11481-011-9287-2.

References

Fourme R, Kahn R, Prange T, Vachette P, Tavernier J, Hauquier G . Structure of tumour necrosis factor by X-ray solution scattering and preliminary studies by single crystal X-ray diffraction. J Mol Biol. 1988; 199(2):389-92. DOI: 10.1016/0022-2836(88)90323-3. View

Kramer S, Aggarwal B, Eessalu T, McCabe S, Ferraiolo B, Figari I . Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res. 1988; 48(4):920-5. View

Seckinger P, Isaaz S, Dayer J . A human inhibitor of tumor necrosis factor alpha. J Exp Med. 1988; 167(4):1511-6. PMC: 2188924. DOI: 10.1084/jem.167.4.1511. View

Beutler B, Cerami A . Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu Rev Biochem. 1988; 57:505-18. DOI: 10.1146/annurev.bi.57.070188.002445. View

Stauber G, Aiyer R, Aggarwal B . Human tumor necrosis factor-alpha receptor. Purification by immunoaffinity chromatography and initial characterization. J Biol Chem. 1988; 263(35):19098-104. View

Stauber G, Aggarwal B . Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937. J Biol Chem. 1989; 264(6):3573-6. View

Jones E, Stuart D, Walker N . Structure of tumour necrosis factor. Nature. 1989; 338(6212):225-8. DOI: 10.1038/338225a0. View

Olsson I, Lantz M, Nilsson E, Peetre C, Thysell H, Grubb A . Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol. 1989; 42(3):270-5. DOI: 10.1111/j.1600-0609.1989.tb00111.x. View

Seckinger P, Isaaz S, Dayer J . Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem. 1989; 264(20):11966-73. View

10.

Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D . A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989; 264(20):11974-80. View

11.

Hohmann H, Remy R, Brockhaus M, van Loon A . Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha). J Biol Chem. 1989; 264(25):14927-34. View

12.

Crump 3rd W, Morin G, Grimm E . Regulation of lymphocyte tumor necrosis factor receptors by IL-2. J Immunol. 1989; 143(7):2236-41. View

13.

Eck M, Sprang S . The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989; 264(29):17595-605. DOI: 10.2210/pdb1tnf/pdb. View

14.

Novick D, Engelmann H, Wallach D, Rubinstein M . Soluble cytokine receptors are present in normal human urine. J Exp Med. 1989; 170(4):1409-14. PMC: 2189483. DOI: 10.1084/jem.170.4.1409. View

15.

Mosley B, Beckmann M, March C, Idzerda R, Gimpel S, Vandenbos T . The murine interleukin-4 receptor: molecular cloning and characterization of secreted and membrane bound forms. Cell. 1989; 59(2):335-48. DOI: 10.1016/0092-8674(89)90295-x. View

16.

Engelmann H, Novick D, Wallach D . Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990; 265(3):1531-6. View

17.

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

18.

Thiele D, Kurosaka M, Lipsky P . Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol. 1983; 131(5):2282-90. View

19.

Pennica D, Nedwin G, Hayflick J, Seeburg P, Derynck R, Palladino M . Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984; 312(5996):724-9. DOI: 10.1038/312724a0. View

20.

Kull Jr F, Jacobs S, Cuatrecasas P . Cellular receptor for 125I-labeled tumor necrosis factor: specific binding, affinity labeling, and relationship to sensitivity. Proc Natl Acad Sci U S A. 1985; 82(17):5756-60. PMC: 390631. DOI: 10.1073/pnas.82.17.5756. View